BR112015027527A2 - intensificador de inibidores do homólogo zeste 2 - Google Patents

intensificador de inibidores do homólogo zeste 2

Info

Publication number
BR112015027527A2
BR112015027527A2 BR112015027527A BR112015027527A BR112015027527A2 BR 112015027527 A2 BR112015027527 A2 BR 112015027527A2 BR 112015027527 A BR112015027527 A BR 112015027527A BR 112015027527 A BR112015027527 A BR 112015027527A BR 112015027527 A2 BR112015027527 A2 BR 112015027527A2
Authority
BR
Brazil
Prior art keywords
zeste
counterpart
enhancer
inhibitor enhancer
inhibitor
Prior art date
Application number
BR112015027527A
Other languages
English (en)
Portuguese (pt)
Inventor
William Blackledge Charles Jr
Su Dai-Shi
Kasparec Jiri
Lorraine Burgess Joelle
I Luengo Juan
Allen Newlander Kenneth
V Lafrance Louis Iii
Schulz Mark
W Johnson Neil
David Knight Steven
Paul Romeril Stuart
Henry Miller William
Tian Xinrong
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112015027527A2 publication Critical patent/BR112015027527A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
BR112015027527A 2013-04-30 2014-04-25 intensificador de inibidores do homólogo zeste 2 BR112015027527A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817436P 2013-04-30 2013-04-30
US201361842038P 2013-07-02 2013-07-02
US201361907024P 2013-11-21 2013-11-21
US201461936460P 2014-02-06 2014-02-06
PCT/IB2014/061012 WO2014177982A1 (en) 2013-04-30 2014-04-25 Enhancer of zeste homolog 2 inhibitors

Publications (1)

Publication Number Publication Date
BR112015027527A2 true BR112015027527A2 (pt) 2017-07-25

Family

ID=50877537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027527A BR112015027527A2 (pt) 2013-04-30 2014-04-25 intensificador de inibidores do homólogo zeste 2

Country Status (20)

Country Link
US (2) US9505745B2 (cg-RX-API-DMAC10.html)
EP (1) EP2991980B1 (cg-RX-API-DMAC10.html)
JP (1) JP6373973B2 (cg-RX-API-DMAC10.html)
KR (1) KR20160003115A (cg-RX-API-DMAC10.html)
CN (1) CN105308038B (cg-RX-API-DMAC10.html)
AU (1) AU2014261075B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015027527A2 (cg-RX-API-DMAC10.html)
CA (1) CA2910873A1 (cg-RX-API-DMAC10.html)
CL (1) CL2015003200A1 (cg-RX-API-DMAC10.html)
DO (1) DOP2015000270A (cg-RX-API-DMAC10.html)
EA (1) EA030196B1 (cg-RX-API-DMAC10.html)
ES (1) ES2717680T3 (cg-RX-API-DMAC10.html)
HK (1) HK1214815A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015015144A (cg-RX-API-DMAC10.html)
NZ (1) NZ630205A (cg-RX-API-DMAC10.html)
PE (1) PE20151981A1 (cg-RX-API-DMAC10.html)
PH (1) PH12015502414A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201508203TA (cg-RX-API-DMAC10.html)
WO (1) WO2014177982A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201507398B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085583B2 (en) * 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
HK1214815A1 (zh) * 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
MA40848A (fr) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
SI3378859T1 (sl) 2015-11-19 2020-03-31 Jiangsu Hengrui Medicine Co., Ltd., Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
WO2017191545A1 (en) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US20170337814A1 (en) * 2016-05-20 2017-11-23 Donald Edward Morgan Safety alerting drivers device and system
US10968215B2 (en) 2016-09-07 2021-04-06 Shanghai Haihe Pharmaceutical Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
CN110964200A (zh) * 2019-12-19 2020-04-07 新纳奇材料科技江苏有限公司 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法
CN114787143A (zh) * 2019-12-23 2022-07-22 四川海思科制药有限公司 Zeste增强子同源物2抑制剂及其用途
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293716A1 (en) * 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
ES2654332T3 (es) * 2009-08-07 2018-02-13 Merck Patent Gmbh Nuevos compuestos azaheterocíclicos
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9730925B2 (en) * 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
HK1214815A1 (zh) * 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂

Also Published As

Publication number Publication date
JP6373973B2 (ja) 2018-08-15
SG11201508203TA (en) 2015-11-27
AU2014261075A1 (en) 2015-11-05
EA201592068A1 (ru) 2016-05-31
KR20160003115A (ko) 2016-01-08
US20170029412A1 (en) 2017-02-02
AU2014261075B2 (en) 2017-01-19
CN105308038B (zh) 2018-05-29
PE20151981A1 (es) 2016-01-14
ES2717680T3 (es) 2019-06-24
DOP2015000270A (es) 2016-02-15
US9505745B2 (en) 2016-11-29
US9790212B2 (en) 2017-10-17
JP2016517878A (ja) 2016-06-20
PH12015502414A1 (en) 2016-02-22
US20160102083A1 (en) 2016-04-14
MX2015015144A (es) 2016-02-18
HK1214815A1 (zh) 2016-08-05
CN105308038A (zh) 2016-02-03
ZA201507398B (en) 2017-01-25
EP2991980A1 (en) 2016-03-09
CA2910873A1 (en) 2014-11-06
NZ630205A (en) 2017-03-31
CL2015003200A1 (es) 2016-04-22
WO2014177982A1 (en) 2014-11-06
EP2991980B1 (en) 2019-01-02
EA030196B1 (ru) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112017008840A2 (pt) intensificador de inibidores do homólogo 2 de zeste
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018072740A2 (pt) realçador de inibidores de homólogo 2 de zeste
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
BR112018074972A2 (pt) derivados de adenosina para uso no tratamento de câncer
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112014018670A8 (pt) Compostos de fórmula, composição farmacêutica, uso de um composto, método para o tratamento e invenção
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2667 DE 15-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.